Cumberland Pharmaceuticals. has filed a patent for a method to prevent or treat Bacillus anthracis (anthrax) infection in mammals by administering telavancin or its salt. The claim specifies the use of telavancin in a pharmaceutical composition with excipients for treating the infection. GlobalData’s report on Cumberland Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cumberland Pharmaceuticals, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Cumberland Pharmaceuticals's grant share as of January 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of anthrax infection with telavancin or its salt
A recently filed patent (Publication Number: US20240024411A1) discloses a method for treating Bacillus anthracis (anthrax) infection in a subject by administering a pharmaceutical composition containing telavancin or its salt along with pharmaceutical excipients. The composition is to be administered intravenously within 15 minutes to 48 hours of diagnosis or exposure to Bacillus anthracis, with a dosage range of 7.5 mg/kg to 15 mg/kg once daily. The method covers various forms of anthrax infections, including cutaneous, gastrointestinal, inhalational, or injection anthrax, and specifies telavancin as the sole antibiotic for treatment.
Moreover, the patent also includes a method for preventing Bacillus anthracis infection in at-risk subjects by administering the same pharmaceutical composition before exposure. The preventive method involves administering the composition less than 24 hours prior to the risk of exposure, with telavancin hydrochloride being the primary antibiotic used. The patent further extends to treating or preventing anthrax infection in mammals by intravenously administering telavancin hydrochloride along with specific excipients once daily. The method emphasizes the use of telavancin as the sole antibiotic for treating or preventing various forms of Bacillus anthracis infection in mammals.
To know more about GlobalData’s detailed insights on Cumberland Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
